Radiobiology of radioimmunotherapy: targeting CD20 B-cell antigen in non-Hodgkin's lymphoma |
| |
Authors: | Hernandez M Carmen Knox Susan J |
| |
Affiliation: | * Department of Radiation Oncology, Stanford University Medical Center, Stanford, CA, USA |
| |
Abstract: | The radiobiology of radioimmunotherapy is an important determinant of both the toxicity and the efficacy associated with the treatment of B-cell non-Hodgkin's lymphoma with radiolabeled anti-CD20 monoclonal antibodies. The properties of the target, CD20, and the mechanisms of action of both the monoclonal antibodies and the associated exponentially decreasing low-dose-rate radiotherapy are described. The radiation dose and dose-rate effects are discussed and related to both the tumor responses and normal organ toxicity. Finally, the use of either unlabeled or radiolabeled anti-CD20 monoclonal antibodies as a component of combined modality therapy (including the sequential or concurrent use of sensitizers) and future directions of the field are discussed. |
| |
Keywords: | Radioimmunotherapy Radiolabeled monoclonal antibody Lymphoma Radiobiology B-cell non-Hodgkin's lymphoma |
本文献已被 ScienceDirect PubMed 等数据库收录! |